Genetic variations in patients have strong impact on their drug therapies and responses because the variations may contribute to the efficacy and/or produce undesirable side effects for any given drug. The Drug Metabolizing Enzymes and Transporters (DMET) assay is a high-throughput technology by Affymetrix that is able to simultaneously genotype variants in multiple genes involved in absorption, distribution, metabolism, and excretion of drugs for subsequent clinical applications, i.e., the assay allows for a precise genetic map that can guide therapeutic interventions and avoid side effects.
Single nucleotide polymorphisms as genomic markers for high-throughput pharmacogenomic studies / Lonetti, Annalisa; Fontana, Maria Chiara; Martinelli, Giovanni; Iacobucci, Ilaria. - ELETTRONICO. - 1368:(2016), pp. 143-159. [10.1007/978-1-4939-3136-1_11]
Single nucleotide polymorphisms as genomic markers for high-throughput pharmacogenomic studies
LONETTI, ANNALISA;FONTANA, MARIA CHIARA;MARTINELLI, GIOVANNI;IACOBUCCI, ILARIA
2016
Abstract
Genetic variations in patients have strong impact on their drug therapies and responses because the variations may contribute to the efficacy and/or produce undesirable side effects for any given drug. The Drug Metabolizing Enzymes and Transporters (DMET) assay is a high-throughput technology by Affymetrix that is able to simultaneously genotype variants in multiple genes involved in absorption, distribution, metabolism, and excretion of drugs for subsequent clinical applications, i.e., the assay allows for a precise genetic map that can guide therapeutic interventions and avoid side effects.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
